DK1196431T3 - En i det væsentlige krystallinsk form af melagatran - Google Patents

En i det væsentlige krystallinsk form af melagatran

Info

Publication number
DK1196431T3
DK1196431T3 DK00946687T DK00946687T DK1196431T3 DK 1196431 T3 DK1196431 T3 DK 1196431T3 DK 00946687 T DK00946687 T DK 00946687T DK 00946687 T DK00946687 T DK 00946687T DK 1196431 T3 DK1196431 T3 DK 1196431T3
Authority
DK
Denmark
Prior art keywords
melagatran
crystalline form
essentially crystalline
essentially
crystalline
Prior art date
Application number
DK00946687T
Other languages
Danish (da)
English (en)
Inventor
Anita Lundblad
Sofia Naagaard
Lena Hedstroem
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1196431T3 publication Critical patent/DK1196431T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
DK00946687T 1999-07-02 2000-06-30 En i det væsentlige krystallinsk form af melagatran DK1196431T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms

Publications (1)

Publication Number Publication Date
DK1196431T3 true DK1196431T3 (da) 2006-12-11

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00946687T DK1196431T3 (da) 1999-07-02 2000-06-30 En i det væsentlige krystallinsk form af melagatran

Country Status (33)

Country Link
US (1) US6479078B1 (xx)
EP (1) EP1196431B1 (xx)
JP (1) JP2003503508A (xx)
KR (1) KR20020020765A (xx)
CN (1) CN100537598C (xx)
AR (1) AR035553A1 (xx)
AT (1) ATE339438T1 (xx)
AU (1) AU765614B2 (xx)
BR (1) BR0012035A (xx)
CA (1) CA2376944A1 (xx)
CY (1) CY1107542T1 (xx)
CZ (1) CZ20014722A3 (xx)
DE (1) DE60030723T2 (xx)
DK (1) DK1196431T3 (xx)
EE (1) EE200100646A (xx)
ES (1) ES2270849T3 (xx)
HK (1) HK1045529B (xx)
HU (1) HUP0202322A3 (xx)
IL (1) IL146972A0 (xx)
IS (1) IS6215A (xx)
MX (1) MXPA01013441A (xx)
MY (1) MY122760A (xx)
NO (1) NO20016419L (xx)
NZ (1) NZ516187A (xx)
PL (1) PL352872A1 (xx)
PT (1) PT1196431E (xx)
RU (1) RU2243973C2 (xx)
SE (1) SE9902550D0 (xx)
SK (1) SK18832001A3 (xx)
TR (1) TR200103855T2 (xx)
TW (1) TWI250991B (xx)
WO (1) WO2001002426A1 (xx)
ZA (1) ZA200109944B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
JP4748449B2 (ja) * 2003-11-27 2011-08-17 味の素株式会社 フェニルアラニン誘導体の結晶及びその製造方法
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
KR20020020765A (ko) 2002-03-15
EP1196431B1 (en) 2006-09-13
CN100537598C (zh) 2009-09-09
HK1045529B (zh) 2007-02-23
US6479078B1 (en) 2002-11-12
HUP0202322A2 (en) 2002-10-28
SE9902550D0 (sv) 1999-07-02
BR0012035A (pt) 2002-03-19
WO2001002426A1 (en) 2001-01-11
EP1196431A1 (en) 2002-04-17
CY1107542T1 (el) 2013-03-13
JP2003503508A (ja) 2003-01-28
CZ20014722A3 (cs) 2002-05-15
CN1359389A (zh) 2002-07-17
AU6040800A (en) 2001-01-22
ZA200109944B (en) 2003-03-03
DE60030723T2 (de) 2007-11-08
TR200103855T2 (tr) 2002-04-22
IL146972A0 (en) 2002-08-14
PT1196431E (pt) 2007-01-31
MY122760A (en) 2006-05-31
TWI250991B (en) 2006-03-11
MXPA01013441A (es) 2002-07-02
DE60030723D1 (de) 2006-10-26
IS6215A (is) 2001-12-27
NO20016419L (no) 2002-03-01
CA2376944A1 (en) 2001-01-11
AR035553A1 (es) 2004-06-16
ES2270849T3 (es) 2007-04-16
PL352872A1 (en) 2003-09-08
HK1045529A1 (en) 2002-11-29
AU765614B2 (en) 2003-09-25
ATE339438T1 (de) 2006-10-15
NO20016419D0 (no) 2001-12-28
SK18832001A3 (sk) 2002-10-08
RU2243973C2 (ru) 2005-01-10
EE200100646A (et) 2003-02-17
HUP0202322A3 (en) 2003-04-28
NZ516187A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
IS5640A (is) Ný kristalla form af Bensímídazól efnasambandi gegn veirum
DK1315694T3 (da) Inhibitorer af alpha-4-medieret celleadhæsion
DK1077943T3 (da) Heterocykliske inhibitorer af p38
DK1049662T3 (da) Inhibitorer af alpha4-medieret celleadhæsion
IS3019B (is) Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
IS7007A (is) Kristallaform af asiþrómýsíni
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1438306T3 (da) Derivater af UK-2A
DK1183345T3 (da) Styret evolution af mikroorganismer
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
DK1261585T3 (da) Substituerede indol-Mannichbaser
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1196431T3 (da) En i det væsentlige krystallinsk form af melagatran
DE60027274D1 (de) Mikroporöser film
NO20023072D0 (no) Syntese av krystallinske silikoaluminofosfater
DK1274427T3 (da) Formulering af substituerede benzimidazoler
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
DK1280803T3 (da) Krystallinsk form II af cabergolin
DK1071330T3 (da) Stabilisering af isothiazolon
DK1155050T3 (da) Fremstilling af polyolefin
IS5821A (is) Kristalluð form af ósanetant